Eli Lilly and Company (NYSE:LLY) Upgraded at Erste Group Bank

Eli Lilly and Company (NYSE:LLY) was upgraded by Erste Group Bank from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Benzinga reports.

Other equities analysts also recently issued reports about the company. Truist Financial restated a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research report on Wednesday, February 21st. Barclays raised their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Finally, Citigroup raised their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $700.00.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $768.20 on Wednesday. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company has a market capitalization of $729.91 billion, a PE ratio of 132.45, a P/E/G ratio of 1.68 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $357.93 and a 12 month high of $800.78. The stock has a 50-day moving average price of $747.98 and a two-hundred day moving average price of $644.13.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period last year, the company earned $2.09 earnings per share. Analysts expect that Eli Lilly and Company will post 12.42 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 12,344 shares of the company’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $634.13, for a total value of $7,827,700.72. Following the sale, the insider now owns 99,543,810 shares in the company, valued at approximately $63,123,716,235.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 180,667 shares of company stock worth $116,186,189 in the last 90 days. Insiders own 0.13% of the company’s stock.

Institutional Trading of Eli Lilly and Company

Institutional investors have recently added to or reduced their stakes in the business. Versant Capital Management Inc increased its position in shares of Eli Lilly and Company by 1.8% in the first quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock worth $573,000 after acquiring an additional 13 shares in the last quarter. Moseley Investment Management Inc. increased its position in shares of Eli Lilly and Company by 0.4% in the first quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock worth $3,027,000 after acquiring an additional 14 shares in the last quarter. Buckhead Capital Management LLC grew its holdings in Eli Lilly and Company by 0.7% during the 4th quarter. Buckhead Capital Management LLC now owns 2,104 shares of the company’s stock valued at $1,226,000 after purchasing an additional 15 shares in the last quarter. Levin Capital Strategies L.P. grew its holdings in Eli Lilly and Company by 3.8% during the 4th quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock valued at $242,000 after purchasing an additional 15 shares in the last quarter. Finally, Clearwater Capital Advisors LLC grew its holdings in Eli Lilly and Company by 1.3% during the 4th quarter. Clearwater Capital Advisors LLC now owns 1,202 shares of the company’s stock valued at $701,000 after purchasing an additional 15 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.